Skip to content
2000
Volume 6, Issue 3
  • ISSN: 1871-5230
  • E-ISSN: 1875-614X

Abstract

Patients with moderate-to-severe psoriasis, will require phototherapy, systemic therapy, or both for adequate disease control. Although a number of well established therapies are available for psoriasis, there are still unmet needs remain, such as longterm safety and practicability. Psoriasis currently regarded as an immune-mediated inflammatory disease, inflammatory response is amplified as a result of increased tumor necrosis factor (TNF) α expression in psoriatic plaques. New biological agents targeting TNFα are promising in psoriasis therapy. Adalimumab is an fully human recombinant IgG 1 monoclonal antibody specific for human TNF α that has been approved for the treatment of rheumatoid arthritis. Adalimumab has only recently been introduced to dermatology. Given the known pathophysiologic role of TNF in psoriasis, this brief review aimed to evaluate the efficacy and safety of adalimumab in the treatment of psoriasis and other dermatoses which it found off-label uses.

Loading

Article metrics loading...

/content/journals/aiaamc/10.2174/187152307781368210
2007-08-01
2025-05-13
Loading full text...

Full text loading...

/content/journals/aiaamc/10.2174/187152307781368210
Loading

  • Article Type:
    Research Article
Keyword(s): Adalimumab; biological agents; psoriasis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test